A novel treatment regimen for muscle-invasive bladder cancer.


­Cisplatin(Cis)-based combination chemotherapy remains the standard of care for metastatic bladder cancer (BC) providing a 5-10% cure rate. Unfortunately up to 60% of patients are ineligible for Cis-based treatment and have the option for carboplatin(Carbo)-based combination chemotherapy. University of Colorado researchers, developed a novel therapy targeting NPEPPS, an M1 aminopeptidase significantly up-regulated in Cis-resistant BC cell lines. When NPEPPS RNA and protein are depleted by siRNA or shRNA, resistant BC cells are re-sensitized to Cis both in vitro and in vivo. Tosedostat, a well-tolerated FDA-approved aminopeptidase inhibitor recapitulated this in BC cells, and importantly with patient derived organoids from Cis-resistant tumors. Thus, this invention is a novel treatment regimen where Tosedostat, or another NPEPPS inhibitor, can be given in combination with platin-based chemotherapy to provide better patient response to chemotherapy and potentially lower the doses necessary for patients. Preliminary findings support NPEPPS as a novel driver of Cis resistance that can be targeted with clinically available inhibitors. Hence, the value of combining these inhibitors with platin regimens can be rapidly tested in clinical trials.

Download Summary Document Here:
For Information, Contact:
Mary Tapolsky
University of Colorado
James Costello
Disease Areas:
For inquiries, email: cuinnovations@cuanschutz.edu.     © 2024. All Rights Reserved. Powered by Inteum